On February 24, 2026, Edesa Biotech, Inc. reported that their drug paridiprubart reduced 28-day mortality from 33% to 24% in a study with 278 patients, showing significant improvements for various conditions. This data highlights its potential efficacy, especially in patients with serious health issues.